您搜索了: polüskleroosiga (爱沙尼亚语 - 英语)

rebifi kasutatakse relapseeruva polüskleroosiga (hulgikoldekõvastumus, sclerosis multiplex) patsientide raviks.
rebif is used to treat patients with relapsing multiple sclerosis (ms).

rebifi uuriti 560 relapseeruva polüskleroosiga patsiendil, kellel oli eelneva kahe aasta jooksul olnud vähemalt kaks relapsi.
the patients had experienced at least two relapses in the previous two years.

rebifi uuriti ka sekundaarse progresseeruva polüskleroosiga patsientidel, vaadeldes kolme aasta vältel ravimi efektiivsust puude süvenemise ennetamisel.
the study looked at the effectiveness of the medicine in preventing the progression of disability over three years.

progresseeruva polüskleroosiga patsientide uuringus ei olnud rebifil olulist mõju puude süvenemisele, kuid relapside sagedus vähenes ligikaudu 30% võrra.
in the study of patients with progressive ms, rebif had no significant effect on the progression of disability, but the relapse rate was reduced by about 30%.

rebifi efektiivsus ei ole tõendatud sekundaarse progresseeruva polüskleroosiga patsientidel (polüskleroosi liik, mis järgneb relapseeruvale polüskleroosile), kelle haiguses ei esine relapse.
rebif’s effectiveness has not been shown in patients with secondary progressive ms (the type of ms that comes after relapsing ms) that is not relapsing.